S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
MarketBeat Week in Review – 11/27 - 12/1
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Mega merger in the works? Humana, Cigna explore big deal
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
US joins in other nations in swearing off coal power to clean the climate
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
At COP28 meeting, oil companies pledge to combat methane. Environmentalists call it a "smokescreen"
BMW recalls SUVs after Takata air bag inflator blows apart, hurling shrapnel and injuring driver

Nektar Therapeutics Stock Price, News & Analysis (NASDAQ:NKTR)

$0.52
+0.04 (+8.25%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.47
$0.53
50-Day Range
$0.42
$0.61
52-Week Range
$0.41
$3.19
Volume
1.13 million shs
Average Volume
1.57 million shs
Market Capitalization
$100.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Nektar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.86 Rating Score
Upside/​Downside
471.4% Upside
$3.00 Price Target
Short Interest
Bearish
4.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.18mentions of Nektar Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$17,474 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.84) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

444th out of 951 stocks

Pharmaceutical Preparations Industry

198th out of 431 stocks


NKTR stock logo

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR Stock Price History

NKTR Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Positive Report for Nektar Therapeutics (NKTR) from TD Cowen
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Recap: Nektar Therapeutics Q3 Earnings
Nektar Therapeutics Q3 Loss decreases, but misses estimates
A Preview Of Nektar Therapeutics's Earnings
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Nektar Therapeutics Q2 Loss decreases, beats estimates
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2023
Today
12/02/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
216
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$6.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+471.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-368,200,000.00
Net Margins
-332.73%
Pretax Margin
-329.36%

Debt

Sales & Book Value

Annual Sales
$92.06 million
Book Value
$0.84 per share

Miscellaneous

Free Float
184,914,000
Market Cap
$100.15 million
Optionable
Optionable
Beta
0.88

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Howard W. RobinMr. Howard W. Robin (Age 70)
    CEO, President & Director
    Comp: $1.83M
  • Mr. Mark A. Wilson (Age 51)
    Senior VP, Chief Legal Officer & Secretary
    Comp: $749.99k
  • Dr. Jonathan Zalevsky Ph.D. (Age 48)
    Senior VP & Chief Research and Development Officer
    Comp: $1.25M
  • Ms. Sandra A. Gardiner (Age 57)
    Chief Financial Officer
  • Vivian Wu
    Director of Investor Relations & Corporate Affairs
  • Mr. Robert Bacci
    Senior Vice President of Human Resources & Facilities Operations
  • Ms. Jennifer Ruddock
    Chief Business Officer
  • Dr. Mary Tagliaferri L.Ac. (Age 57)
    M.D., Chief Medical Officer
  • Dr. Loui T. Madakamutil
    VP and Head of Discovery & Research














NKTR Stock Analysis - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" NKTR shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price target for 2024?

7 brokers have issued twelve-month price targets for Nektar Therapeutics' stock. Their NKTR share price targets range from $1.00 to $6.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 471.4% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 on January 1st, 2023. Since then, NKTR shares have decreased by 76.8% and is now trading at $0.5250.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The biopharmaceutical company had revenue of $20.50 million for the quarter, compared to analyst estimates of $20.94 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 80.44% and a negative net margin of 332.73%. During the same period in the prior year, the firm posted ($0.85) EPS.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.80%), Acadian Asset Management LLC (4.00%), Primecap Management Co. CA (3.77%), Jacobs Levy Equity Management Inc. (2.57%), Monaco Asset Management SAM (2.53%) and AQR Capital Management LLC (1.92%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, Robert Chess and Roy A Whitfield.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NKTR) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -